Chalcogen Bonded Directly To Ring Carbon Of The Hetero Ring Patents (Class 514/460)
  • Patent number: 11678683
    Abstract: The invention related to a processed edible product comprising a complex of at least one antimicrobial compound and a polyelectrolyte complex of a polyanion and a polycation. The invention further relates to a method for producing a processed edible product comprising a complex of at least one antimicrobial compound and a polyelectrolyte complex of a polyanion and a polycation, to a method for preventing spoilage of a processed edible product, and to a method of preventing, reducing and/or eliminating the presence of fungi, bacteria and/or viruses on a processed edible product. The invention additionally relates to a use of a complex of a antimicrobial compound and a polyelectrolyte complex of a polyanion and a polycation for preventing, reducing and/or eliminating the presence of fungi, bacteria and/or viruses on a processed edible product.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: June 20, 2023
    Assignee: Ceradis B.V.
    Inventors: Jacobus Stark, Wilhelmus Maria van der Krieken, Christiaan Gerardus Johannes Maria Jans
  • Patent number: 11622939
    Abstract: An HS-25 tablet, an HS-25 solid dispersion composition, a preparation method therefor and usage thereof. The HS-25 tablet is made by using HS-25 and excipients for wet granulation, drying, granulating and tablet pressing.
    Type: Grant
    Filed: November 23, 2018
    Date of Patent: April 11, 2023
    Assignee: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.
    Inventors: Li Ding, Jun Dai, Chunrong Feng, Changliang Dai
  • Patent number: 11236059
    Abstract: The present invention is directed to novel natural product-derived ratjadone-based compounds useful as payloads (or toxins) in drug-conjugates constructs with cell target binding moieties (CTBM) and payload-linker compounds useful in connection with drug conjugates. The present invention further relates to new ratjadone compositions including the aforementioned payloads, payload-linkers and drug conjugates, and methods for using these payloads, payload-linkers and drug conjugates, to treat pathological conditions including cancer, inflammatory and infectious diseases.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: February 1, 2022
    Assignee: HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH
    Inventors: Philipp Klahn, Mark Broenstrup, Verena Fetz, Wera Collisi, Katrin I Mohr, Stephan Huettel, Werner Tegge
  • Patent number: 11166937
    Abstract: Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: November 9, 2021
    Assignee: Amazentis SA
    Inventors: Christopher L. Rinsch, William Blanco-Bose, Bernard Schneider, Charles Thomas, Carmen Sandi, Johan Auwerx, Penelope Andreux, Richardus Houtkooper, Eija Pirinen, Laurent Mouchiroud, David Genoux
  • Patent number: 11155529
    Abstract: Methods for producing ferric maltol compositions, such as ferric trimaltol, from elemental iron, and ferric maltol compositions produced by these methods and their uses are described.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: October 26, 2021
    Assignee: SHIELD TX (UK) LIMITED
    Inventors: Jonathan Joseph Powell, Nuno Jorge Rodrigues Faria
  • Patent number: 11142520
    Abstract: The invention provides compounds of formula (I), stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof: (I) wherein A1 to A6 and R1 to R4 are as defined herein. Such compounds are suitable for use in the treatment or prevention of diseases or conditions which are mediated by the activation of lactate dehydrogenase A (LDHA), for example cancer.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: October 12, 2021
    Assignee: ARCTIC PHARMA AS
    Inventors: Jo Klaveness, Bora Sieng, Steffi Lundvall, Claudia Alejandra Bøen, Kathrin Hnida
  • Patent number: 11104955
    Abstract: The instant disclosure provides methods and compositions related to discovery of MAP2K (MEK1) as a therapeutic target for treatment or prevention of arteriovenous malformations (AVMs). Therapeutic and/or prophylactic uses and compositions of known MEK1 inhibitors, including small molecules and nucleic acid agents, are described.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: August 31, 2021
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Arin K. Greene, Matthew Warman, Yue Huang
  • Patent number: 11066381
    Abstract: A urolithin-containing aqueous solution containing urolithin and collagen, a dried solid composition thereof, methods for producing these, and a stabilization method for urolithin.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: July 20, 2021
    Assignee: DAICEL CORPORATION
    Inventor: Takanori Nakajima
  • Patent number: 11020373
    Abstract: Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: June 1, 2021
    Assignee: Amazentis SA
    Inventors: Christopher Lawrence Rinsch, William Blanco-Bose, Bernard Schneider, Laurent Mouchiroud, Dongryeol Ryu, Penelope Andreux, Johan Auwerx
  • Patent number: 10918111
    Abstract: The present invention provides an antimicrobial composition for coating surfaces that enables a reduction of up to one hundred percent of the microbial activity on any type of frequently used substrate or surface, comprising a compound of micronized high-purity metallic copper particles. Moreover, a process for preparing the composition is provided.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: February 16, 2021
    Assignee: ATACANALAB
    Inventors: Marisol Gómez Álvarez, Claudio Guillermo Ramírez Mora
  • Patent number: 10912756
    Abstract: Pharmaceutical composition comprising an aqueous solution of a taxane and an aqueous solution of a hydrophobic statin intended for use in treatment or prevention of human melanoma.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: February 9, 2021
    Assignee: UNIWERSYTET JAGIELLONSKI
    Inventors: Wojciech Placha, Jacek Zagajewski, Małgorzata Szczygieł, Monika Piwowar
  • Patent number: 10889574
    Abstract: The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: January 12, 2021
    Assignees: DAEWOONG PHARMACEUTICAL CO., LTD., GREEN CROSS CORPORATION
    Inventors: Hee-kyoon Yoon, Se-Hwan Park, Ji-sung Yoon, Soongyu Choi, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, Kwang-Seop Song, Min Ju Kim, So Ok Park
  • Patent number: 10785978
    Abstract: Control and repellency of biting flies, house flies, ticks, ants, fleas, biting midges, cockroaches, spiders and stink bugs is obtained by contact of the insects with at least one of the compounds of the structure (I) wherein R is —OH, ?O, —OC(O)R4, —OR6, or —(OR6)2, wherein each R6 is independently an alkyl group containing from 1 to 4 carbon atoms and R4 is a branched or straight chain, saturated or unsaturated, hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; X is O or CH2, with the proviso that when X is O R can only be ?O: each Z is independently (CH) or (CH2); y is a numeral selected from 1 and 2; R1 is H or a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; R2 is H and a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to three double bonds and from 1 to 15 carbon atoms; R3 is H, a branched or straight chain, saturated or unsaturated hydrocarbyl gro
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: September 29, 2020
    Assignee: Bedoukian Research, Inc.
    Inventor: Robert H. Bedoukian
  • Patent number: 10688109
    Abstract: A method of preventing or reducing the occurrence of malondiadehyde and/or levuglandin protein modification in a subject in need thereof, comprising administering to said subject an effective amount of at least one ?-KA scavenger compound, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: June 23, 2020
    Assignee: Vanderbilt University
    Inventors: John A. Oates, Olivier Boutaud, Irene Zagol-Ikapitte
  • Patent number: 10640496
    Abstract: The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: May 5, 2020
    Assignees: DAEWOONG PHARMACEUTICAL CO., LTD., GREEN CROSS CORPORATION
    Inventors: Hee-kyoon Yoon, Se-Hwan Park, Ji-sung Yoon, Soongyu Choi, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, Kwang-Seop Song, Min Ju Kim, So Ok Park
  • Patent number: 10610489
    Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a SGLT-2 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.
    Type: Grant
    Filed: September 30, 2010
    Date of Patent: April 7, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Peter Schneider, Wolfram Eisenreich, Nantharat Pearnchob
  • Patent number: 10555930
    Abstract: This present invention relates to a complex of a glucopyranosyl derivative and L-pyroglutamic acid as a sodium dependent glucose cotransporter (SGLT) inhibitor, and preparation processes thereof, and a pharmaceutical composition containing the complex, and their uses in the manufacture of a medicament for treating diabetes and/or diabetes-related diseases.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: February 11, 2020
    Assignee: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED
    Inventors: Pengcho Tang, Zheng Gu, Wuyong Wu, Zongyuan Zhang, Panpan Kang, Tong Qu
  • Patent number: 10398653
    Abstract: The present invention provides a method for producing a pharmaceutical composition which is a tablet and which contains tofogliflozin as an active ingredient. The method comprises mixing an additive and tofogliflozin to prepare a powder mixture and obtaining a tablet from the powder mixture by direct compression. The additive comprises at least one filler.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: September 3, 2019
    Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Kenta Wada, Tomoaki Hirayama, Kenichi Sakai, Shiho Yoshimura
  • Patent number: 10383949
    Abstract: Provided are compounds comprising a self-immolative group, and the compounds comprising a self-immolative group according to the present invention may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: August 20, 2019
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Yong Zu Kim, Tae Kyo Park, Sung Ho Woo, Sun Young Kim, Jong Un Cho, Doo Hwan Jung, Ji Young Min, Hyang Sook Lee, Yun Hee Park, Jeong Hee Ryu, Kyu Man Oh, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Jeon Yang
  • Patent number: 10351590
    Abstract: Provided herein are synthetic analogs of withanolide natural products of formula (I), wherein R1-R4 are as defined herein, and their pharmaceutical uses in treating neurodegenerative diseases.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: July 16, 2019
    Assignees: Imstar Therapeutics Inc., Universite Laval
    Inventors: Anthony A. Shaw, Jean-Pierre Julien, Agnes H. Chan
  • Patent number: 10307419
    Abstract: This invention relates to a tablet containing, as an active ingredient, 7-[4-(4-benzo[b]thiophen-4-yl -piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, that has excellent disintegration ability, storage stability and photostability. The tablet of the present invention comprising an uncoated tablet containing 7-[4-(4-benzo[b]thiophen-4 -yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, excipients such as lactose, corn starch, and microcrystalline cellulose; disintegrants such as low-substituted hydroxypropylcellulose, croscarmellose sodium, and sodium carboxymethyl starch; binders such as hydroxypropylcellulose; lubricants such as stearate; and further comprising a coating layer, containing hypromellose; talc; titanium oxide; colorant; and the like, the coating layer being applied to the surface of the uncoated tablet.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: June 4, 2019
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventor: Yoshiharu Inoue
  • Patent number: 10231930
    Abstract: The present invention provides a method for producing a pharmaceutical composition which is a tablet and which contains tofogliflozin as an active ingredient. The method comprises mixing an additive and tofogliflozin to prepare a powder mixture and obtaining a tablet from the powder mixture by direct compression. The additive comprises at least one filler.
    Type: Grant
    Filed: December 26, 2014
    Date of Patent: March 19, 2019
    Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Kenta Wada, Tomoaki Hirayama, Kenichi Sakai, Shiho Yoshimura
  • Patent number: 10179157
    Abstract: The present invention discloses a slim and aqueous extract of Garcinia cambogia comprising (?)-hydroxycitric acid as dietary product for weight management. The present invention also discloses a process of preparation of aqueous extract wherein the Garcinia cambogia fruit rinds are subjected to cold circulation to retain the phytochemical components and the aqueous extract is adjusted to neutral pH and stabilized with triple mineral salt of calcium, magnesium and potassium and decolorized using activated carbon. The colorless, odorless aqueous extract obtained is subjected to qualitative and quantitative analysis to obtain pure concentrate, which is useful in food, beverage and pharmaceutical industries as dietary supplement. The concentrate equivalent to 1500 mg of (?)-hydroxycitric acid on dried basis is used for the consumption with the distilled water. The slim and aqueous extract concentrate of Garcinia cambogia is useful in treatment of overweight, obesity and hypercholesterolemia.
    Type: Grant
    Filed: February 15, 2016
    Date of Patent: January 15, 2019
    Inventors: Venkatachalam Hariharan, PradeepKumar Siddavvanahalli Virupakshappa, Kanchana Hariharan, Vinayaka Neechadi Puppadar, Paranjothi Kanni
  • Patent number: 10149830
    Abstract: The instant disclosure is related to lactone-containing compounds of formula (I), compositions thereof, and use thereof for treating proliferative disease or disorders. Also provided herein are methods of making, identifying, or characterizing the compounds, or compositions thereof.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: December 11, 2018
    Assignee: Cushing Academy
    Inventor: William R. Sponholtz, III
  • Patent number: 10040776
    Abstract: A compound of formula (I) is provided wherein R represents a linear or branched C5 alkyl group, as well as the use of such compounds in a fragrant and/or flavoring composition, or as a masking agent for odors and/or flavors.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: August 7, 2018
    Assignee: V. MANE FILS
    Inventors: Jean Mane, Caroline Plessis, Jean-Jacques Chanot
  • Patent number: 9914969
    Abstract: The present invention relates methods to increase the expression of fatty acid desaturases (FADS) and increase cellular and tissue levels of highly unsaturated fatty acids (HUFA) by modulating one or more of the FADS via the action of specific classes of drugs (e.g., statins and LXR agonists). The present invention also relates to methods of treating conditions (e.g., tumor and cancer) involving deficient function of FADS by administering statins and/or LXR agonists. The present invention further relates to methods of determining the need for statins or dietary LCPUFA in subjects.
    Type: Grant
    Filed: January 28, 2013
    Date of Patent: March 13, 2018
    Assignee: CORNELL UNIVERSITY
    Inventors: James Thomas Brenna, Holly Turner Reardon, Sesha Durga Kumar Kothapalli
  • Patent number: 9750759
    Abstract: A compound of general formula (I) wherein A, Y, R1, R2, R3, R4, R5, and R6 take various meaning or use in the treatment of cancer.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: September 5, 2017
    Assignee: Pharma Mar, S.A.
    Inventors: Alberto Rodriquez Vicente, Maria Garranzo Garcia-Ibarrola, Carmen Murcia Perez, Francisco Sanchez Sancho, Maria del Carmen Cuevas Marchante, Cristina Mateo Urbano, Isabel Digon Juarez
  • Patent number: 9630764
    Abstract: An oxygen-absorbing resin composition copolymerized polyolefin compound including a copolymerized polyolefin compound and a transition metal catalyst, wherein the copolymerized polyolefin compound is a copolymerized polyolefin compound including at least one of constitutional unit (a) selected from the group consisting of the constitutional units represented by the general formula (1), and at least one of the constitutional unit (b) having an indane ring, selected from the group consisting of the constitutional units represented by the general formulas (2) and (3).
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: April 25, 2017
    Assignee: MITSUBISHI GAS CHEMICAL COMPANY, INC.
    Inventors: Shinpei Iwamoto, Satoshi Okada, Shinichi Ikeda
  • Patent number: 9540307
    Abstract: The present invention relates to novel statin derivatives of omega-3 fatty acids, and their use in treating hypercholesterolemia, obesity, hypertriglyceridemia, cardiovascular diseases, and metabolic diseases, and Alzheimer's disease.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: January 10, 2017
    Assignee: JIVA PHARMA, INC.
    Inventor: Om P Goel
  • Patent number: 9434684
    Abstract: To provide a novel pesticide, especially a fungicide and a nematocide.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: September 6, 2016
    Assignee: Nissan Chemical Industries, Ltd.
    Inventors: Motoyoshi Iwasa, Keisuke Tsuji, Mitsutaka Tomizawa, Takeshi Mita, Hidehito Kuwahara, Miho Asahi, Hotaka Imanaka
  • Patent number: 9345671
    Abstract: The present invention provides a pharmaceutical composition for enhancement of adiponectin production, treatment or prevention of hypoadiponectinemia, and the like, comprising as an active ingredient an HMG-CoA reductase inhibitor.
    Type: Grant
    Filed: April 27, 2004
    Date of Patent: May 24, 2016
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Toshiyuki Takagi, Iichiro Shimomura, Yuji Matsuzawa, Tohru Funahashi
  • Patent number: 9321777
    Abstract: The disclosure relates to compounds of formula (I): wherein , A, W, X, and Ra are as defined in the disclosure, and salts thereof, and to pharmaceutical compositions comprising said compounds, to processes for preparing them, and to their use as medicaments, in particular as MET inhibitors.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: April 26, 2016
    Assignee: SANOFI
    Inventors: Eva Albert, Eric Bacque, Conception Nemecek, Antonio Ugolini, Sylvie Wentzler
  • Patent number: 9314029
    Abstract: Control or repellency of mosquitoes is accomplished by bringing the insects into contact with at least one of the compounds of the structure (I) wherein R is selected from —OH, ?O, —OC(O)R4, —OR6, —(OR6)2, wherein each R6 is independently selected from an alkyl group containing from 1 to 4 carbon atoms and R4 is a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; X is O or CH2, with the proviso that when X is O R can only be ?O; each Z is independently selected from (CH) and (CH2); y is a numeral selected from 1 and 2; R1 is selected from H or a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; R2 is selected from H and a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to three double bonds and from 1 to 15 carbon atoms; R3 is selected from the group consisting of H and a branched or straight chain, saturated o
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: April 19, 2016
    Assignee: Bedoukain Research, Inc.
    Inventor: Robert H. Bedoukian
  • Patent number: 9307783
    Abstract: Homeopathic water compositions are described, as well as beverage articles for making drinking water formulations with such compositions. One such beverage article includes a water bottle, and a dispensing cap adapted to be secured to the water bottle. The dispensing cap contains dried homeopathic composition-coated sucrose or sucrose/starch particles that are dispensable into water in the water bottle by user actuation of the dispensing cap, to constitute the homeopathic water formulation for consumption.
    Type: Grant
    Filed: July 29, 2012
    Date of Patent: April 12, 2016
    Assignee: ESSENTIALIFE HOMEOPATHICS
    Inventor: Ramin Stephan Bayani
  • Patent number: 9241914
    Abstract: The present invention concerns a method of enhancing milk production by a ruminant that includes providing a feed that contains sorbitol and at least one additional feed component, and orally feeding the feed to the ruminant, the ruminant ingesting about 100 grams, or less, of sorbitol per day.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: January 26, 2016
    Assignee: Land O'Lakes, Inc.
    Inventor: Cindie M. Luhman
  • Patent number: 9089612
    Abstract: This invention also provides a method to prevent, control, and treat a lipid metabolism disorder, a biliary disorder, cardiovascular disease, obesity or an endocrine disorder by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cGMP-dependent phosphodieasterases.
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: July 28, 2015
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventor: Kunwar Shailubhai
  • Publication number: 20150148347
    Abstract: A compound of formula I, wherein the groups R1, R2, R3, X, m, and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.
    Type: Application
    Filed: November 25, 2014
    Publication date: May 28, 2015
    Inventors: Iain LINGARD, Dieter HAMPRECHT
  • Publication number: 20150148411
    Abstract: Provided are compositions and methods related to mutations in the Myh9 gene for aiding in diagnosing a subject as having an aggressive form of a cancer, for identifying an individual as a candidate for treatment with a nuclear export inhibitor, for determining whether tumor cells have defective p53 nuclear transportation, and for treating an individual diagnosed with an aggressive cancer.
    Type: Application
    Filed: November 25, 2014
    Publication date: May 28, 2015
    Inventors: Daniel Schramek, Elaine Fuchs
  • Publication number: 20150148410
    Abstract: An isolated peptidic fragment of apolipoprotein E comprises at least 3 contiguous amino acids, Including glycosylated threonine 194, threonine 289, serine 94, or serine 76 of SEQ ID NO.: 1, or any combination of those. An antibody capable of binding to the isolated peptidic fragment. A method of detecting a naturally-occurring circulating atherogenic low-density lipoprotein in a plasma sample from an individual, comprising qualitatively and/or quantitatively detecting in a low-density lipoprotein that binds to the antibody. A method of assessing an individual's risk of ischemic heart disease and/or atherosclerosis comprises quantifying in a plasma sample from the individual an amount of apolipoprotein E comprising glycosylated threonine 194, threonine 289, serine 94 or serine 76 of SEQ ID NO.: 1, or any combination of those.
    Type: Application
    Filed: September 10, 2012
    Publication date: May 28, 2015
    Applicant: Texas Heart Institute
    Inventors: Chu-Huang Chen, Liang-Yin Ke
  • Patent number: 9034921
    Abstract: A compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney is disclosed. A pharmaceutical composition including the compound as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes is disclosed. A method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound is provided.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: May 19, 2015
    Assignee: GREEN CROSS CORPORATION
    Inventors: Soongyu Choi, Kwang Seop Song, Suk Ho Lee, Min Ju Kim, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, So Ok Park, Hyunku Kang, Myung Eun Jung, Kinam Lee, Hyun Jung Kim, Jun Sung Lee, Min Woo Lee, Mi-Soon Kim, Dong Ho Hong, Misuk Kang
  • Publication number: 20150133540
    Abstract: Control or repellency of mosquitoes is accomplished by bringing the insects into contact with at least one of the compounds of the structure (I) wherein R is selected from —OH, ?O, —OC(O)R4, —OR6, —(OR6)2, wherein each R6 is independently selected from an alkyl group containing from 1 to 4 carbon atoms and R4 is a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; X is O or CH2, with the proviso that when X is O R can only be ?O; each Z is independently selected from (CH) and (CH2); y is a numeral selected from 1 and 2; R1 is selected from H or a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; R2 is selected from H and a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to three double bonds and from 1 to 15 carbon atoms; R3 is selected from the group consisting of H and a branched or straight chain, satur
    Type: Application
    Filed: April 30, 2013
    Publication date: May 14, 2015
    Inventor: Robert H. Bedoukian
  • Patent number: 9029413
    Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, and in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. Antiviral activity of enzyme inhibitors is demonstrated.
    Type: Grant
    Filed: April 3, 2012
    Date of Patent: May 12, 2015
    Assignee: The Trustees of Princeton University
    Inventors: Josh Munger, Bryson Bennett, Thomas Shenk, Joshua Rabinowitz
  • Publication number: 20150119414
    Abstract: A composition and a method of treatment utilizing a combination of statins (or HMG-CoA reductase inhibitors), a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught.
    Type: Application
    Filed: January 2, 2015
    Publication date: April 30, 2015
    Applicant: PIVOTAL THERAPEUTICS INC.
    Inventors: George JACKOWSKI, Rachelle MACSWEENEY, Nisar Ahmad SHAIKH, Jason YANTHA, Valerie B. SCHINI-KERTH
  • Publication number: 20150110871
    Abstract: The present invention relates to a gastric retentive tablet composition comprising: (1) coated particles essentially consisting of a drug and an amino methacrylate copolymer, (2) a methacrylic acid copolymer and (3) an excipient, wherein items 1, 2, and 3 are blended together, and then compressed into a gastric retentive tablet. Thus, the coated particles (item 1), a methacrylic acid copolymer and the excipient are evenly distributed in the tablet. The excipient is selected from a group consisting of a retarding agent, a binder, a filler, a chelating agent, a diluent, a disintegrant, a lubricant, a colorant, a solubilizing agent, or a mixture thereof. The coated particles (item 1) do not contain methacrylic acid polymer.
    Type: Application
    Filed: January 3, 2015
    Publication date: April 23, 2015
    Inventor: David Wong
  • Publication number: 20150104504
    Abstract: The present disclosure provides pharmaceutical compositions of statins and polyunsaturated fatty acids (PUFAs), in which the statins are dissolved in the PUFAs, the PUFA species being present substantially in the free acid form. Also provided are oral unit dosage forms of the disclosed pharmaceutical compositions and methods of treating blood lipid disorders using the compositions and oral unit dosage forms.
    Type: Application
    Filed: May 7, 2013
    Publication date: April 16, 2015
    Inventors: Bernardus Machielse, Timothy J. Maines, Michael H. Davidson, Bharat M. Mehta
  • Patent number: 9006468
    Abstract: The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the following structure is disclosed.
    Type: Grant
    Filed: January 25, 2012
    Date of Patent: April 14, 2015
    Assignee: Dow AgroSciences, LLC.
    Inventors: Gary D. Crouse, Thomas C. Sparks, CaSandra L. McLeod, David A. Demeter, Kristy Bryan, Annette V. Brown, William H. Dent, III, Denise P. Cudworth, Jaime S. Nugent, Ricky Hunter, Jack G. Samaritoni
  • Publication number: 20150094323
    Abstract: Methods of treating or preventing cardiovascular disease and/or inflammatory disease in mammalian subjects comprising the administration of the novel formulations disclosed herein are provided.
    Type: Application
    Filed: December 8, 2014
    Publication date: April 2, 2015
    Inventor: Susanne Riel
  • Publication number: 20150094322
    Abstract: Pharmaceutical compositions of colchicine for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined or desired release profile. Methods of treating or preventing cardiovascular disease and/or inflammatory disease in mammalian subjects comprising the administration of the novel formulations disclosed herein are also provided.
    Type: Application
    Filed: December 8, 2014
    Publication date: April 2, 2015
    Inventor: Susanne Riel
  • Publication number: 20150080463
    Abstract: Methods are provided for diagnosing the risk of a cardiovascular event in a patient. In some embodiments, the method includes measuring the level of proprotein convertase subtilisin kexin type 9 (PCSK9) in a sample obtained from a patient and comparing the measured level of PCSK9 to a control. Also provided are methods of selecting a therapy for a patient prior to administration of the therapy. In some embodiments, the method includes measuring a PCSK9 blood concentration in a sample from a patient to determine the presence or absence of a PCSK9 blood concentration indicative of responsiveness to an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Further provided are methods for assessing the efficacy of a therapy being administered to a patient. In certain embodiments, the method includes detecting a change in a PCSK9 blood concentration in a sample from a patient, wherein a change in detected levels is indicative of whether the therapy is efficacious.
    Type: Application
    Filed: March 16, 2011
    Publication date: March 19, 2015
    Applicant: BG MEDICINE, INC.
    Inventor: Pieter Muntendam
  • Publication number: 20150065567
    Abstract: Administration of certain 1-phenylalkanecarboxylic acid derivatives is useful for treating, preventing and/or reducing the risk of developing Alzheimer's Disease and multiple sclerosis.
    Type: Application
    Filed: August 15, 2014
    Publication date: March 5, 2015
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Bruno Imbimbo, Marina Pizzi, Daniel Chain